ArticleMolecular biology reports2026
Multi-carbapenemase-producing Klebsiella pneumoniae: Genomic characterization and In Vitro evaluation of cefiderocol and novel β-lactam/β-lactamase inhibitor combinations.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMulti-carbapenemase-producing Klebsiella pneumoniae (MCP-Kp) represents an emerging threat due to its extensive drug resistance and the scarcity of effective therapeutic options. This study characterizes the epidemiology, genomic features, and in vitro activity of novel antimicrobial agents against MCP-Kp isolates recovered from bloodstream infections in Italy. METHODS AND
resultsFrom 2022 to 2023, a total of 414 non-duplicate carbapenemase-producing K. pneumoniae isolates were collected from 14 Italian hospitals. Antimicrobial susceptibility testing of the MCP-Kp isolates included cefiderocol, aztreonam/avibactam, cefepime/zidebactam, cefepime/enmetazobactam and relevant comparators. Whole-genome sequencing was performed to determine multilocus sequence types (STs), capsule loci, plasmid replicons, resistance determinants, and virulence-associated genes. MCP isolates accounted for 2.4% of all carbapenemase producers and displayed six distinct carbapenemase combinations. Genomic analysis revealed a polyclonal population (ST512, ST147, ST383, ST35, ST320, ST6668) characterized by heterogeneous capsule loci, diverse plasmid replicons, extensive β-lactamase repertoires, porin alterations, and widespread non-β-lactam resistance determinants. Two isolates carried mgrB disruptions associated with colistin resistance. MCP isolates exhibited high-level resistance to most β-lactams and to first- and second-generation β-lactam/β-lactamase inhibitor combinations. Aztreonam/avibactam, cefepime/zidebactam, and cefiderocol retained potent in vitro activity, with susceptibility rates of 100%, 100%, and 80%, respectively. Synergy was consistently observed between aztreonam and ceftazidime/avibactam, meropenem/vaborbactam, or cefepime/enmetazobactam across all aztreonam-resistant, metallo-β-lactamase-producing MCP-Kp isolates.
conclusionsMCP-Kp in Italy exhibited substantial genomic diversity and multidrug resistance, driven by horizontal gene transfer and plasmid-mediated dissemination. The preserved activity of aztreonam/avibactam and cefepime/zidebactam, alongside the observed synergistic combinations, underscores promising therapeutic strategies for managing infections caused by these highly resistant pathogens.
Indexed as
Identifiers
42859255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.